Jiuyuan Gene seeks IPO cash for bet on weight-loss drugs
The developer of treatments for cancer and bone fractures is branching out into the weight-loss market, but faces strong competition there Key Takeaways: At present, Jiuyuan Gene relies heavily on…
Recent Articles
RELATED ARTICLES
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US -
CSPC Pharma weighs up diet drug for bigger bottom line
1093.HK
- InSilico seeks IPO boost to get AI drugs over the line
-
Kintor shares plunge after hair-loss drug flops in clinical trials
9939.HK
-
Everest reaches new heights on growing drug sales
1952.HK
-
Profit setback for Simcere Pharma in novel drugs quest
2096.HK
-
Kintor Pharma eyes regeneration with over-the-counter cosmetic treatments
9939.HK
